ZBH Zimmer Biomet Holdings Inc

Solventum, a 3M spinoff, overcame initial investor unrest in 2025 by selling its purification and filtration business for $4 billion and acquiring Acera Surgical for $850 million. These strategic moves allowed the company to pay down debt, streamline its portfolio, and attract renewed investor confidence, leading to a significant turnaround in its financial performance and stock price. CEO Bryan Hanson's focus on efficiency and a decentralized structure has positioned the company for positive momentum in 2026.

Stryker (SYK) shares closed down 0.5% in cautious year-end trading, with investors focused on a December 31st dividend record date and a January 1st leadership change as Spencer Stiles becomes President and COO. The stock is holding near a $350 support level, and the company has declared a quarterly dividend of $0.88 per share. The broader market also saw a pullback in the final week of 2025.

Boston Trust Walden Corp recently reduced its stake in Zimmer Biomet Holdings, Inc. by 4.8% in the third quarter, now holding 660,128 shares valued at $65.02 million. This move comes as analysts have adopted a more cautious stance on the stock, with a consensus "Hold" rating and an average price target of $107.50. Despite beating Q3 EPS estimates, Zimmer Biomet slightly missed revenue expectations and has set its FY2025 EPS guidance between $8.10 and $8.30, while also announcing a $0.24 quarterly dividend.

The Collagen Meniscus Implant Market is projected for strong growth from 2025 to 2032 due to rising demand, expanding applications, and technological advancements. A new report by Coherent Market Insights details market size, revenue trends, key growth factors, and competitive landscapes, offering actionable insights for data-driven decisions. Leading companies like Zimmer Biomet Holdings Inc. and RTI Surgical Holdings Inc. are highlighted in this comprehensive analysis.

Kempner Capital Management Inc. has significantly reduced its stake in Zimmer Biomet Holdings, Inc., selling 27,095 shares, which accounts for 46.3% of its previous holding. Following this transaction, the firm now owns 31,401 shares of Zimmer Biomet, valued at approximately $3.09 million, making it the 15th largest position in its portfolio. The medical equipment provider recently reported earnings that slightly beat EPS expectations but missed revenue forecasts, while analysts hold a "Hold" rating with an average target price of $107.50 for the stock.

QSM Asset Management Ltd significantly increased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the third quarter, making it their largest position. The medical equipment provider also reported strong third-quarter earnings, beating analyst EPS estimates and showing a 9.6% year-over-year revenue increase with positive FY 2025 guidance. Institutional investors hold a substantial portion of the company's stock, and Zimmer Biomet recently declared a quarterly dividend.